Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Annals of Neurology

Volumn 69, Issue 3, 2011, Pages 570-580

  Shi, Min ^a   Bradner, Joshua ^a   Hancock, Aneeka M ^a   Chung, Kathryn A ^b   Quinn, Joseph F ^b   Peskind, Elaine R ^a,c   Galasko, Douglas ^d   Jankovic, Joseph ^e   Zabetian, Cyrus P ^a,c   Kim, Hojoong M ^a,c   Leverenz, James B ^a,c   Montine, Thomas J ^a   Ginghina, Carmen ^a   Kang, Un Jung ^f   Cain, Kevin C ^a   Wang, Yu ^a,g   Aasly, Jan ^h   Goldstein, David ⁱ   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

ⁱ NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; DJ 1 PROTEIN; FLT3 LIGAND; FRACTALKINE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHEMOKINE CX3CL1; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FMS-LIKE TYROSINE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE SYSTEM ATROPHY; ONCOGENE PROTEINS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 79953283868     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22311     Document Type: Article

References (52)

1. Jellinger KA., Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18 (Suppl 6): S2-S12. (Pubitemid 37185190)
2. Litvan I, Halliday G, Hallett M, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 2007; 66: 251-257. (Pubitemid 46559017)
3. Paviour DC, Price SL, Jahanshahi M, et al. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 2006; 21: 989-996. (Pubitemid 44184601)
4. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
5. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149-158.
6. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173. (Pubitemid 351355295)
7. Eller M, Williams DR., Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009; 5: 561-570.
8. O'Keeffe GC, Michell AW, Barker RA., Biomarkers in Huntington's and Parkinson's disease. Ann N Y Acad Sci 2009; 1180: 97-110.
9. McKinnon JH, Demaerschalk BM, Caviness JN, et al. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders ? Neurologist 2007; 13: 382-385. (Pubitemid 350307683)
10. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008; 213: 315-325.
11. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349: 162-166. (Pubitemid 44331776)
12. Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss ? Neurosci Lett 2009; 450: 332-335.
13. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345: 967-972. (Pubitemid 43776502)
14. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-726.
15. Thomas B, Beal MF., Parkinson's disease. Hum Mol Genet 2007; 16 (Spec No. 2): R183-R194.
16. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008; 129: 526-529. (Pubitemid 352029270)
17. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46: 1052-1060.
18. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
19. Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-1781. (Pubitemid 32881189)
20. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009; 24: 2203-2210.
21. Bibl M, Mollenhauer B, Lewczuk P, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007; 12: 671-680. (Pubitemid 46998250)
22. Mollenhauer B, Bibl M, Esselmann H, et al. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis ? J Neural Transm 2007; 114: 919-927. (Pubitemid 47013596)
23. Yasuda M, Ito T, Oono T, et al. Fractalkine and TGF-beta1 levels reflect the severity of chronic pancreatitis in humans. World J Gastroenterol 2008; 14: 6488-6495.
24. Fevang B, Yndestad A, Damas JK, et al. Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation. Clin Immunol Immunopathol 2009; 130: 151-161.
25. Kim TS, Lim HK, Lee JY, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2008; 436: 196-200.
26. Hampel H, Burger K, Teipel SJ, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4: 38-48.
27. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746. (Pubitemid 47058377)
28. Mandal PK, Pettegrew JW, Masliah E, et al. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 2006; 31: 1153-1162. (Pubitemid 44379676)
29. Montine TJ, Shi M, Quinn JF, et al. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010: 15; 25: 2682-2685.
30. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006; 22: 200-208. (Pubitemid 44310515)
31. Bibl M, Esselmann H, Mollenhauer B, et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 2007; 103: 467-474. (Pubitemid 47498016)
32. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008; 64: 850-855.
33. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2007; 254: IV-IV/7 /2-IV/7.
34. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid (1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-579. (Pubitemid 30251740)
35. Holmberg B, Johnels B, Blennow K, Rosengren L., Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003; 18: 186-190. (Pubitemid 36305463)
36. Kanemaru K, Kameda N, Yamanouchi H., Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54: 1875-1876. (Pubitemid 30428428)
37. Verbeek MM, Abdo WF, De Jong D, et al. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Mov Disord 2004; 19: 238-240 231; author reply 240-231.
38. Abdo WF, Bloem BR, Van Geel WJ, et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007; 28: 742-747. (Pubitemid 46349352)
39. Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett 1997; 238: 139-141. (Pubitemid 28034342)
40. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-630. (Pubitemid 32397998)
41. Jansen Steur E, Vermes I, de Vos RA., Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 1998; 351: 1105-1106. (Pubitemid 28162212)
42. Kahle PJ, Jakowec M, Teipel SJ, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 2000; 54: 1498-1504. (Pubitemid 30210474)
43. Drexler HG, Quentmeier H., FLT3: receptor and ligand. Growth Factors 2004; 22: 71-73. (Pubitemid 38923309)
44. Chua SJ, Bielecki R, Wong CJ, et al. Neural progenitors, neurons and oligodendrocytes from human umbilical cord blood cells in a serum-free, feeder-free cell culture. Biochem Biophys Res Commun 2009; 379: 217-221.
45. Brazel CY, Ducceschi MH, Pytowski B, Levison SW., The FLT3 tyrosine kinase receptor inhibits neural stem/progenitor cell proliferation and collaborates with NGF to promote neuronal survival. Mol Cell Neurosci 2001; 18: 381-393. (Pubitemid 33052340)
46. Biber K, Neumann H, Inoue K, Boddeke HW., Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007; 30: 596-602. (Pubitemid 350051426)
47. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998; 95: 10896-10901. (Pubitemid 28413165)
48. Block ML, Hong JS., Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98. (Pubitemid 41242883)
49. Fuhrmann M, Bittner T, Jung CK, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010; 13: 411-413.
50. Denes A, Ferenczi S, Halasz J, et al. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008; 28: 1707-1721.
51. Schlachetzki JC, Hull M., Microglial activation in Alzheimer's disease. Curr Alzheimer Res 2009; 6: 554-563.
52. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-924. (Pubitemid 43980506)